Compositions and methods for regulation of active TNF-.alpha.

Details Compositions and methods for regulation of active TNF-.alpha. Compositions and methods for regulation of active TNF-.alpha.

1995-06-07

2000-02-01

Achutamurthy, Ponnathapura

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514825, 514822, 514826, 514885, 514886, 536 175, 536 21, 536 552, 424 851, A01N 4304, A61K 4505, A61K 3900, C07H 1500

Patent

active

060203234

ABSTRACT:
Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.

REFERENCES:
patent: 4401662 (1983-08-01), Lormeau et al.
patent: 4446314 (1984-05-01), Jordan
patent: 4539398 (1985-09-01), Rosenberg
patent: 4607025 (1986-08-01), Petitou et al.
patent: 4727063 (1988-02-01), Naggi et al.
patent: 4774231 (1988-09-01), Petitou et al.
patent: 4801583 (1989-01-01), Petitou et al.
patent: 4818816 (1989-04-01), Petitou et al.
patent: 4889808 (1989-12-01), Rappaport
patent: 4933326 (1990-06-01), Bianchini et al.
patent: 4943630 (1990-07-01), Jacquinet et al.
patent: 4973580 (1990-11-01), Mascellani et al.
patent: 4981955 (1991-01-01), Lopez
patent: 4987223 (1991-01-01), Choay et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5010063 (1991-04-01), Piani et al.
patent: 5034520 (1991-07-01), Lormeau et al.
Asselot et al., "Heparin Fragments Regulate Collagen Phentotype And Fibronectin Synthesis In The Skin Of Genetically Diabetic Mice," Biochem. Pharmacol. 38:895-899 (1989).
Asselot-Chapel et al., "Biosynthesis Of Interstitial Collagens And Fibronectin By Porcine Aorta Smooth Muscle Cells. Modulation By Low-Molecular Weight Heparin Fragments," Biochim. Biophys. Acta 993:240-244 (1989).
Horvath et al., "Low Dose Heparin And Early Kidney Transplant Function," Aust. N.Z. J. Med. 5:537-539 (1975).
Lider et al. "Suppression Of Experimental Autoimmune Diseases And Prolongation Of Allograft Survival By Treatment Of Animals With Low Doses of Heparins," J. Clin. Invest. 83:752-756 (1989).
Lider et al., "Inhibition of T Lymphocyte Heparanase By Heparin Prevents T Cell Migration And T Cell-Mediated Immunity," Eur. J. Immunol. 20:493-499 (1990).
Naparstek et al., "Activated T Lymphocytes Produce A Matrix-Degrading Heparan Sulphate Endoglycosidase," Nature 310:241-244 (1984).
Psuja, "Affinity of Binding of Radiolabeled (.sup.125 I) Heparin and Low Molecular Weight Heparin Fraction CY 222 to Endothelium in Culture," Folio. Haematol. (Leipz) 114:429-436 (1987).
Toivonen et al., "Rat Adjuvant Arthritis as a Model to Test Potential Antirheumatic Agents," Meth. and Find. Exp. Clin. Pharmacol. 4(6):359-363 (1982).
Kariya et al., "Preparation of Unsaturated Disaccharides by Eliminative Cleavage of Heparin And Heparan Sulfate With Heparitinases," Comp. Biochem. Physiol. 103B:473-479 (1992).

Affiliated with

Also associated with

Rating

Compositions and methods for regulation of active TNF-.alpha. does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for regulation of active TNF-.alpha., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for regulation of active TNF-.alpha. will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-937641